Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 157

1.

Imaging of melanoma using 64Cu- and 86Y-DOTA-ReCCMSH(Arg11), a cyclized peptide analogue of alpha-MSH.

McQuade P, Miao Y, Yoo J, Quinn TP, Welch MJ, Lewis JS.

J Med Chem. 2005 Apr 21;48(8):2985-92.

PMID:
15828837
2.

Synthesis and biologic evaluation of 64Cu-labeled rhenium-cyclized alpha-MSH peptide analog using a cross-bridged cyclam chelator.

Wei L, Butcher C, Miao Y, Gallazzi F, Quinn TP, Welch MJ, Lewis JS.

J Nucl Med. 2007 Jan;48(1):64-72.

3.

Gallium-68-labeled DOTA-rhenium-cyclized alpha-melanocyte-stimulating hormone analog for imaging of malignant melanoma.

Wei L, Miao Y, Gallazzi F, Quinn TP, Welch MJ, Vāvere AL, Lewis JS.

Nucl Med Biol. 2007 Nov;34(8):945-53. Epub 2007 Sep 4.

4.

Modification of the structure of a metallopeptide: synthesis and biological evaluation of (111)In-labeled DOTA-conjugated rhenium-cyclized alpha-MSH analogues.

Cheng Z, Chen J, Miao Y, Owen NK, Quinn TP, Jurisson SS.

J Med Chem. 2002 Jul 4;45(14):3048-56. Erratum in: J Med Chem 2002 Sep 26;45(20):4588.

PMID:
12086490
5.

Radiofluorinated rhenium cyclized α-MSH analogues for PET imaging of melanocortin receptor 1.

Ren G, Liu S, Liu H, Miao Z, Cheng Z.

Bioconjug Chem. 2010 Dec 15;21(12):2355-60. doi: 10.1021/bc100391a. Epub 2010 Nov 12.

6.

A gallium-labeled DOTA-alpha-melanocyte- stimulating hormone analog for PET imaging of melanoma metastases.

Froidevaux S, Calame-Christe M, Schuhmacher J, Tanner H, Saffrich R, Henze M, Eberle AN.

J Nucl Med. 2004 Jan;45(1):116-23.

7.

64Cu-labeled alpha-melanocyte-stimulating hormone analog for microPET imaging of melanocortin 1 receptor expression.

Cheng Z, Xiong Z, Subbarayan M, Chen X, Gambhir SS.

Bioconjug Chem. 2007 May-Jun;18(3):765-72. Epub 2007 Mar 10.

8.

Small-animal PET of melanocortin 1 receptor expression using a 18F-labeled alpha-melanocyte-stimulating hormone analog.

Cheng Z, Zhang L, Graves E, Xiong Z, Dandekar M, Chen X, Gambhir SS.

J Nucl Med. 2007 Jun;48(6):987-94. Epub 2007 May 15.

9.

Evaluation of an (111)In-DOTA-rhenium cyclized alpha-MSH analog: a novel cyclic-peptide analog with improved tumor-targeting properties.

Chen J, Cheng Z, Owen NK, Hoffman TJ, Miao Y, Jurisson SS, Quinn TP.

J Nucl Med. 2001 Dec;42(12):1847-55.

11.

Synthesis and biological evaluation of a novel (177)Lu-DOTA-[Gly(3)-cyclized(Dap(4), (d)-Phe(7), Asp(10))-Arg(11)]α-MSH(3-13) analogue for melanocortin-1 receptor-positive tumor targeting.

Lim JC, Hong YD, Kim JJ, Choi SM, Baek HS, Choi SJ.

Cancer Biother Radiopharm. 2012 Oct;27(8):464-72. doi: 10.1089/cbr.2011.1140. Epub 2012 Jul 25.

PMID:
22831553
12.

Metastatic melanoma imaging with an (111)In-labeled lactam bridge-cyclized alpha-melanocyte-stimulating hormone peptide.

Guo H, Shenoy N, Gershman BM, Yang J, Sklar LA, Miao Y.

Nucl Med Biol. 2009 Apr;36(3):267-76. doi: 10.1016/j.nucmedbio.2009.01.003.

13.

Reduction of the ring size of radiolabeled lactam bridge-cyclized alpha-MSH peptide, resulting in enhanced melanoma uptake.

Guo H, Yang J, Gallazzi F, Miao Y.

J Nucl Med. 2010 Mar;51(3):418-26. doi: 10.2967/jnumed.109.071787. Epub 2010 Feb 11.

15.

203Pb-labeled alpha-melanocyte-stimulating hormone peptide as an imaging probe for melanoma detection.

Miao Y, Figueroa SD, Fisher DR, Moore HA, Testa RF, Hoffman TJ, Quinn TP.

J Nucl Med. 2008 May;49(5):823-9. doi: 10.2967/jnumed.107.048553. Epub 2008 Apr 15.

16.

PET of malignant melanoma using 18F-labeled metallopeptides.

Ren G, Liu Z, Miao Z, Liu H, Subbarayan M, Chin FT, Zhang L, Gambhir SS, Cheng Z.

J Nucl Med. 2009 Nov;50(11):1865-72. doi: 10.2967/jnumed.109.062877. Epub 2009 Oct 16.

17.

Gallium-67-labeled lactam bridge-cyclized alpha-melanocyte stimulating hormone peptide for primary and metastatic melanoma imaging.

Guo H, Yang J, Shenoy N, Miao Y.

Bioconjug Chem. 2009 Dec;20(12):2356-63. doi: 10.1021/bc900428x.

18.

111In-DOTA-Re(Cys3,4,10,d-Phe7,Arg11)αMSH3-13.

Cheng KT, Cheng Z, Quinn TP.

Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004-2013.
2007 Sep 1 [updated 2007 Dec 17].

19.

Development of high-specific-activity (68)Ga-labeled DOTA-rhenium-cyclized alpha-MSH peptide analog to target MC1 receptors overexpressed by melanoma tumors.

Cantorias MV, Figueroa SD, Quinn TP, Lever JR, Hoffman TJ, Watkinson LD, Carmack TL, Cutler CS.

Nucl Med Biol. 2009 Jul;36(5):505-13. doi: 10.1016/j.nucmedbio.2009.01.017. Epub 2009 May 7.

PMID:
19520291
20.

Effect of DOTA position on melanoma targeting and pharmacokinetic properties of 111In-labeled lactam bridge-cyclized alpha-melanocyte stimulating hormone peptide.

Guo H, Yang J, Gallazzi F, Prossnitz ER, Sklar LA, Miao Y.

Bioconjug Chem. 2009 Nov;20(11):2162-8. doi: 10.1021/bc9003475.

Supplemental Content

Support Center